@article{Allegretti:2024:10.1053/j.gastro.2024.05.004,
author = {Allegretti, JR and Khanna, S and Mullish, BH and Feuerstadt, P},
doi = {10.1053/j.gastro.2024.05.004},
journal = {Gastroenterology},
title = {The progression of microbiome therapeutics for the management of gastrointestinal diseases and beyond},
url = {http://dx.doi.org/10.1053/j.gastro.2024.05.004},
year = {2024}
}

Download

TY  - JOUR
AB  - There has been an increased ability to investigate human microbiota through next-generation sequencing and functional assessment. This advancement has rapidly expanded our ability to study and manipulate the gastrointestinal microbiome to mitigate disease. Fecal microbiota transplantation, a therapy that broadly transfers the entire intestinal ecosystem, has been explored as a potential therapeutic in a variety of gastrointestinal, hepatic, and extraintestinal conditions. The field, however, continues to evolve, with a movement toward precision microbiome therapeutics individualizing care for various disorders. This review will describe the use of fecal microbiota transplantation, microbiota restoration, and precision microbiome therapeutics focusing on gastrointestinal and hepatic diseases.
AU  - Allegretti,JR
AU  - Khanna,S
AU  - Mullish,BH
AU  - Feuerstadt,P
DO  - 10.1053/j.gastro.2024.05.004
PY  - 2024///
SN  - 0016-5085
TI  - The progression of microbiome therapeutics for the management of gastrointestinal diseases and beyond
T2  - Gastroenterology
UR  - http://dx.doi.org/10.1053/j.gastro.2024.05.004
UR  - https://www.sciencedirect.com/science/article/pii/S0016508524049151
UR  - http://hdl.handle.net/10044/1/112352
ER  - 

Download